Rinath M Jeselsohn

32PUBLICATIONS
273CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersTumour immunologyHealth and ecological risk assessment
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (32)

|Nov 29, 2025
Cellular reprogramming during anti-PD-1 and chemotherapy treatment in early-stage primary hormone receptor-positive breast cancer.

Jingxin Fu, Adrienne G Waks, Erica Pimenta

|Nov 28, 2025
Efficacy, safety, and predictive biomarkers of neoadjuvant nab-paclitaxel and pembrolizumab in hormone receptor-positive breast cancer: A randomized pilot trial.

Adrienne G Waks, Jingxin Fu, Xiangying Chu

|Aug 25, 2025
Circulating Tumor Cell Dynamics after CDK4/6 Inhibitor for Hormone Receptor-Positive Metastatic Breast Cancer: A Biomarker Analysis from the PACE Phase II Study.

Lorenzo Gerratana, Carolina Reduzzi, Yue Ren

|Aug 22, 2025
Tamoxifen induces PI3K activation in uterine cancer.

Kirsten Kübler, Agostina Nardone, Shankara Anand

|May 13, 2025
Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative metastatic breast cancer: a phase II trial (NIMBUS).

Romualdo Barroso-Sousa, Jorge Gomez Tejeda Zanudo, Tianyu Li

|Apr 26, 2025
MUC1-C dependency in drug resistant HR+/HER2- breast cancer identifies a new target for antibody-drug conjugate treatment.

Ayako Nakashoji, Atrayee Bhattacharya, Hiroki Ozawa

Pageof 6

Frequent Collaborators

11 joint publications

Sara M Tolaney

5 joint publications

Agostina Nardone

5 joint publications

Douglas Russo

5 joint publications

Cristina Guarducci